International Stem Cell Corp. (OTCMKTS:ISCO) Short Interest Down 89.7% in August

International Stem Cell Corp. (OTCMKTS:ISCO) was the recipient of a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 808 shares, a decline of 89.7% from the August 15th total of 7,881 shares. Based on an average daily volume of 92,036 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are sold short.

International Stem Cell Stock Performance

Shares of International Stem Cell stock traded down $0.01 during trading hours on Thursday, reaching $0.36. The company’s stock had a trading volume of 28,587 shares, compared to its average volume of 29,057. The company’s 50 day simple moving average is $0.31 and its 200 day simple moving average is $0.22. International Stem Cell has a one year low of $0.12 and a one year high of $0.54. The stock has a market cap of $2.88 million and a P/E ratio of -4.50.

International Stem Cell (OTCMKTS:ISCO) last announced its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.01) earnings per share for the quarter. The company had revenue of $2.67 million for the quarter.

International Stem Cell Company Profile

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.